Merger with a Future: DORDA Advises on Successful Takeover of Assign DMB by P95
September, 2024 - Austria
DORDA has successfully advised P95, a global leader in epidemiological and clinical solutions, on its acquisition of the Austrian CRO Assign DMB. The M&A team, led by M&A Partner Lukas Herrmann, with support from Senior Associate Georg Durstberger (Corporate) and Associate Bianca Schamberger (M&A), advised P95 on this transaction, in collaboration with McDermott Will & Emery (UK) and Quinz (Belgium).
P95 is further expanding its global footprint with this acquisition. Assign DMB, renowned for its expertise in clinical data management and biostatistics, particularly in infectious diseases and vaccines, is a perfect complement to P95's service portfolio.
"We are very pleased to have advised P95 on this strategically significant acquisition. Working with P95 has been highly professional and enjoyable," said Lukas Herrmann. "Combining the expertise of both companies will strengthen P95's market position and unlock new growth opportunities."
The acquisition of Assign DMB reinforces P95's position as a leading provider of clinical research services worldwide. The two companies complement each other perfectly, offering their clients an even more comprehensive range of services going forward.
